Delpharm welcomed Bruno Delie as its new Chief Commercial Officer.

Delpharm is a worldwide leader in contract manufacturing and development of medicines with : - 19 plants in France, Italy, Canada, Poland and The Netherlands - Over 1,1 billion euros turnover - Over 6,500 people - 6,500 people working in the company - Most dosage forms produced For over 35 years, Delpharm has grown by progressively acquiring production plants, notably from major pharmaceutical laboratories. Today, Delpharm operates 18 industrial sites and 3 development centers located in France, Italy, Canada, the Netherlands, and Poland, producing over one billion boxes of medicines per year and contributing to the development of numerous projects. As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules. Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.